LiveGrow Bio, a provider of advanced microbial formulation and manufacturing solutions, and T3 BioScience, Inc., a developer of novel microbial crop protection products, today announced plans to collaborate in 2025 on the development of a new biopesticide derived from a Gram-negative bacterial strain.

T3 BioScience, a University of Wisconsin Research Foundation startup established in 2012 and guided by the pioneering research of Dr. Ching-Hong Yang at the University of Wisconsin-Milwaukee (UWM), focuses on creating products capable of reducing the need for antibiotics in agriculture. Through its proprietary discovery platform, PROMISA, T3 BioScience has identified novel bacteria with performance comparable to traditional antibiotics and chemical solutions.

The collaboration will leverage LiveGrow Bio’s proprietary formulation technology to provide T3 BioScience a commercially viable product formulation for biocontrol living bacteria early in the development process. This approach aims to reduce the time and cost traditionally associated with bringing Gram-negative microbial solutions to market.

Unlike conventional methods where formulation occurs late in development, this partnership will enable T3 BioScience to conduct early-stage greenhouse trials, followed by field trials, using a formulation aligned with market requirements. By integrating formulation at this early stage, the companies expect to streamline validation processes, ensure data consistency, and potentially save years of additional testing.

For Gram-negative microbes—often challenging and expensive to commercialize—LiveGrow Bio’s formulation process offers a viable path forward. It is designed to maintain a two-year shelf life at room temperature and a microbial concentration of at least 10⁶ cfu/g, meeting the requirements of existing agricultural distribution networks. This stability, along with potential manufacturing cost reductions of up to 95% compared to conventional methods, enhances the prospect of bringing innovative Gram-negative microbial products profitably to market.

“T3 BioScience’s strong fundamental research capabilities and innovative microbial discoveries make them an ideal partner for applying our patented technology,” said Andrey Pinchuk, CEO of LiveGrow Bio. “Having a great microbe is a crucial first step, but turning it into a stable, profitable commercial product is where we come in. We’re proud to work alongside T3 BioScience to help bring their innovations to the agricultural market more efficiently and cost-effectively.”

This collaboration may serve as a model for other research-driven organizations seeking effective, sustainable, and commercially scalable bio-control agents. By combining T3 BioScience’s research strengths with LiveGrow Bio’s formulation expertise, both companies aim to help shape the future of biological crop protection.

About LiveGrow Bio
LiveGrow Bio specializes in delivering advanced microbial formulation and manufacturing solutions that shorten R&D timelines, reduce costs, and ensure long-term shelf stability. By providing ready-to-use, commercial-grade formulations from the outset, LiveGrow Bio enables companies to gather meaningful trial data more quickly and transition seamlessly to large-scale production and distribution.

About T3 BioScience
T3 BioScience, Inc., founded in 2012, emerged from Dr. Ching-Hong Yang’s research at UWM, with the UWM-Research Foundation initiating this biotech startup in 2012. Dedicated to developing agricultural biocontrol agents that reduce reliance on antibiotics, T3 BioScience employs its proprietary discovery methodology PROMISA to identify potent novel natural bacteria from the environment. The company will submit later in 2025 its first product, RejuAgro, to the EPA for regulatory approval, with additional bio-control agents in earlier stages of development.